MedTrace Logo

Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer

NCT03983538 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-05-12

No results posted yet for this study

Summary

This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.

Conditions

Interventions

OTHER

Mathematical modeling to predict response to chemotherapy

Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.

Sponsors & Collaborators

  • New Mexico Cancer Research Alliance

    lead OTHER

Principal Investigators

  • Ursa Brown-Glaberman, MD · University of New Mexico Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-02
Primary Completion
2018-01-28
Completion
2018-01-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03983538 on ClinicalTrials.gov